Magrolimab联合利妥昔单抗治疗复发/难治性惰性非霍奇金淋巴瘤:1/2期试验3年随访
该1b/2期试验评估Magrolimab联合利妥昔单抗(M+R)治疗复发/难治性惰性非霍奇金淋巴瘤的长期安全性和疗效。46例患者中42例为滤泡性淋巴瘤、4例为边缘区淋巴瘤,中位随访36.7个月,客观缓解率52.2%,完全缓解率30.4%,中位缓解持续时间15.9个月,中位无进展生存期7.4个月,总生存期未达到。
要点
- M+R在复发/难治性惰性非霍奇金淋巴瘤中3年随访显示长期安全性,未报告新的毒性。
- 客观缓解率52.2%,完全缓解率30.4%,中位缓解持续时间15.9个月。
- 中位无进展生存期7.4个月(95%CI 4.8-13.0),中位总生存期未达到。
核心结论
- M+R在复发/难治性惰性非霍奇金淋巴瘤患者中显示出长期安全性和疗效,支持进一步探索基于CD47的治疗联合方案。
研究设计与样本
- 1b/2期试验,1b期M+R组分为4组,接受10至45 mg/kg magrolimab联合375 mg/m2利妥昔单抗;2期探索30和45 mg/kg magrolimab。
- 共46例患者接受治疗,其中42例为滤泡性淋巴瘤,4例为边缘区淋巴瘤。
- 主要终点为治疗中出现的不良事件(TEAE)和客观缓解率(ORR);次要终点包括缓解持续时间(DOR)、无进展生存期(PFS)和总生存期(OS)。
主要发现
- 所有患者均发生至少1例任何级别的TEAE,44例报告至少1例治疗相关TEAE。
- 长期随访期间未报告新的毒性,无治疗相关死亡。
- 中位随访36.7个月(范围1.2-62.3个月)。
- ORR为52.2%,其中30.4%达到完全缓解;中位DOR为15.9个月,中位至缓解时间为1.8个月。
- 中位PFS为7.4个月(95%CI 4.8-13.0),中位OS未达到。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) is generally considered incurable with current treatment options. Previous phase 1b/2 results showed combining magrolimab (anti-cluster-of-differentiation [CD] 47 antibody) with the anti-CD20 antibody rituximab (M+R) has antitumor activity against R/R iNHL. We report 3-year follow-up data from this phase 1b/2 study assessing long-term safety and efficacy of M+R in R/R iNHL. After magrolimab priming, 4 patient groups in phase 1b M+R received 10 to 45-mg/kg magrolimab doses with 375 mg/m2 rituximab. Phase 2 explored 30 and 45 mg/kg magrolimab. Primary end points were treatment-emergent adverse events (TEAEs) and objective response rate (ORR). Secondary end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Exploratory analysis included circulating tumor DNA, biomarkers of magrolimab tumor penetration, and drug target expression assessments. Of 46 patients treated in phase 1b/2, 42 had follicular lymphoma and 4 had marginal zone lymphoma. All patients experienced ≥1 any-grade TEAE, and 44 reported ≥1 treatment-related TEAE. No additional toxicities were reported during long-term follow-up, and there were no treatment-related deaths. Median follow-up was 36.7 (range, 1.2-62.3) months. The ORR was 52.2%, with 30.4% achieving a complete response. The median DOR was 15.9 months, and median time-to-response was 1.8 months. Median PFS and OS were 7.4 (95% confidence interval, 4.8-13.0) months and not reached, respectively. These results demonstrate the long-term safety and efficacy of M+R in patients with iNHL and support further exploration of CD47-based treatment combinations. This trial was registered at www.ClinicalTrials.gov as #NCT02953509.
引用
- Mehta A, Popplewell L, Collins GP, et al. Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial. Blood Adv. 2024. PMID: 39213421. doi:10.1182/bloodadvances.2024013277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。